Likelihood of PAH in Scleroderma Patients May Be Evident in Specific Autoantibodies

Researchers in Italy developed a clear way of exploring differences in autoantibodies to predict which scleroderma patients are likely to develop pulmonary arterial hypertension (PAH), improving their chances of getting appropriate treatment before changes in their lung blood vessels take place. The study, “Subspecificities of anticentromeric protein A antibodies identify…